| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools. 
|
|
Today’s Big NewsFeb 3, 2025 |
|
Wednesday, February 26, 2025 | 11am ET / 8am PT Discover how the convergence of spatial biology, AI, and computational tools is transforming cancer research. This webinar explores high-multiplex spatial analysis, tumor heterogeneity, and advances in precision medicine, reshaping drug development. Register now to learn how these innovations are driving breakthroughs in oncology. 
|
|
| By Fraiser Kansteiner With President Donald Trump’s tariffs about to take hold, industry groups are warning that the move could hamstring U.S. pharmaceutical supplies and productivity, and put an extra strain on patients’ wallets, too. |
|
|
|
By Conor Hale The Trump White House plans to install 25% tariffs on goods from Canada and Mexico, complicating the supply chains of many U.S. medtech manufacturers. |
By Darren Incorvaia The Centers for Disease Control and Prevention has asked its staff to withdraw any scientific papers currently under consideration for internal or external publication so that certain words can be removed, according to several reports. |
By Kevin Dunleavy Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. According to a Massachusetts Worker Adjustment and Retraining Notification report from last week, the company will lay off 300 workers at its viral vector manufacturing facilities in Cambridge and Plainville |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights. 
|
|
By Conor Hale The news comes just days after Baxter completed the sale of its Vantive kidney care unit through a $3.8 billion deal with the Carlyle Group that had been in the works since last summer. |
By Zoey Becker Among its various international efforts, USAID works to strengthen global supply chains and promote access to essential medicines. |
By Zoey Becker Sen. Elizabeth Warren (D-MA) and Sen. Ron Wyden (D-OR) requested that RFK Jr. commit to recusing himself from vaccine-related decisions if confirmed as the secretary of the Department of Health and Human Services (HHS). |
By Nick Paul Taylor Novartis has become the latest drugmaker to get in trouble over an employee’s LinkedIn likes. The U.K. drug marketing watchdog ruled the employee’s act broke the rules on advertising prescription medicines to the public but placed the blame on the worker, not the company. |
By James Waldron Irish biotech GH Research has said the phase 2 win for its inhaled depression drug has “paved the way for future commercial success.” |
By Conor Hale The head of the FDA’s artificial intelligence-focused Digital Center of Excellence, Troy Tazbaz, is departing the agency during what he described as the early stages of a "technological revolution" in healthcare. |
By Nick Paul Taylor Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August. The news led Affibody to claim its former partner “has not been able to fully capitalize” on the asset’s potential. |
By Angus Liu Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in positive trial results that could set it up for a full approval. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
